Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival

Fig. 5

Kaplan–Meier plot showing the breast cancer-specific survival of the methylation risk groups based on changes in methylation from before to after NACT. A The methylation risk score separated the risk groups significantly (p value = 0.0034) in our cohort. B The risk score was validated in an independent cohort of locally advanced breast cancer patients receiving NACT (p value = 0.049). C The risk score separated the risk groups significantly in patients receiving monotherapy epirubicin (p = 0.035) and paclitaxel (p = 0.033), but not a combination of the two. EpiTax: epirubicin followed by paclitaxel in case of inferior response or paclitaxel followed by epirubicin in case of inferior response

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us